Medtronic Receives the US FDA’s Approval for its PulseSelect PFA System to Treat Atrial Fibrillation
Shots:
- The US FDA-approved PulseSelect Pulsed Field Ablation (PFA) System is designed for the treatment of paroxysmal & persistent atrial fibrillation. The safety, efficacy & efficiency of this system were evaluated in a study named (PULSED AF) that depicted 0.7% safety event & 80% clinical success rates in both indications
- The PulseSelect PFA system is designed with safety features that provide a rapid PVI through consistent and predictable energy delivery & catheter maneuverability
- It is a plug-and-play system used with any mapping system, with built-in features like phrenic nerve test pulse & a non-therapeutic low voltage pulse, fixed catheter (9) spacing for contiguous ablation (can also be used for pacing & sensing)
Ref: Medtronic | Image: Medtronic
Related Post:- Medtronic Reports (PULSED AF) Trial Results of PulseSelect PFA System for Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
